RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

Current stock price

27.71 USD
+0.35 (+1.28%)
Last:

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • In the past year RIGL was profitable.
  • In the past year RIGL had a positive cash flow from operations.
  • In multiple years RIGL reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 71.46%, RIGL belongs to the top of the industry, outperforming 99.42% of the companies in the same industry.
  • RIGL has a Return On Equity of 93.75%. This is amongst the best in the industry. RIGL outperforms 99.42% of its industry peers.
  • RIGL's Return On Invested Capital of 23.92% is amongst the best of the industry. RIGL outperforms 97.87% of its industry peers.
Industry RankSector Rank
ROA 71.46%
ROE 93.75%
ROIC 23.92%
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400

1.3 Margins

  • RIGL has a better Profit Margin (124.72%) than 98.65% of its industry peers.
  • With an excellent Operating Margin value of 42.63%, RIGL belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
  • RIGL has a Gross Margin of 93.33%. This is amongst the best in the industry. RIGL outperforms 94.20% of its industry peers.
  • RIGL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 42.63%
PM (TTM) 124.72%
GM 93.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

6

2. RIGL Health Analysis

2.1 Basic Checks

  • RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, RIGL has more shares outstanding
  • Compared to 5 years ago, RIGL has less shares outstanding
  • The debt/assets ratio for RIGL has been reduced compared to a year ago.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • RIGL has an Altman-Z score of 1.40. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.40, RIGL is in the better half of the industry, outperforming 63.06% of the companies in the same industry.
  • The Debt to FCF ratio of RIGL is 0.69, which is an excellent value as it means it would take RIGL, only 0.69 years of fcf income to pay off all of its debts.
  • RIGL's Debt to FCF ratio of 0.69 is amongst the best of the industry. RIGL outperforms 95.16% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that RIGL is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.06, RIGL is in line with its industry, outperforming 40.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.69
Altman-Z 1.4
ROIC/WACC2.49
WACC9.6%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.42 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a worse Current ratio (2.42) than 71.95% of its industry peers.
  • A Quick Ratio of 2.30 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a worse Quick ratio (2.30) than 71.18% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.3
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

5

3. RIGL Growth Analysis

3.1 Past

  • RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 593.62%, which is quite impressive.
  • The Revenue has grown by 64.15% in the past year. This is a very strong growth!
  • RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.06% yearly.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%

3.2 Future

  • RIGL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.44% yearly.
  • Based on estimates for the next years, RIGL will show a small growth in Revenue. The Revenue will grow by 6.25% on average per year.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

8

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.25, which indicates a rather cheap valuation of RIGL.
  • Compared to the rest of the industry, the Price/Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.84% of the companies listed in the same industry.
  • RIGL is valuated cheaply when we compare the Price/Earnings ratio to 26.21, which is the current average of the S&P500 Index.
  • RIGL is valuated cheaply with a Price/Forward Earnings ratio of 6.69.
  • Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 98.65% of the companies in the same industry.
  • RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.13.
Industry RankSector Rank
PE 4.25
Fwd PE 6.69
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 99.03% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
  • 98.84% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.76
EV/EBITDA 2.25
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%

0

5. RIGL Dividend Analysis

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (4/7/2026, 1:21:02 PM)

27.71

+0.35 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners91.09%
Inst Owner Change0%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap511.80M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (88.45%)
Short Float %20.83%
Short Ratio10.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)8.94%
PT rev (3m)12.94%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.83%
Revenue NQ rev (1m)4.24%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE 4.25
Fwd PE 6.69
P/S 1.74
P/FCF 6.76
P/OCF 6.76
P/B 1.31
P/tB 1.4
EV/EBITDA 2.25
EPS(TTM)6.52
EY23.53%
EPS(NY)4.14
Fwd EY14.95%
FCF(TTM)4.1
FCFY14.78%
OCF(TTM)4.1
OCFY14.78%
SpS15.93
BVpS21.2
TBVpS19.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.76
Profitability
Industry RankSector Rank
ROA 71.46%
ROE 93.75%
ROCE 30.28%
ROIC 23.92%
ROICexc 38.21%
ROICexgc 42.24%
OM 42.63%
PM (TTM) 124.72%
GM 93.33%
FCFM 25.71%
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.69
Debt/EBITDA 0.18
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 19.09
Cash Conversion 59.16%
Profit Quality 20.61%
Current Ratio 2.42
Quick Ratio 2.3
Altman-Z 1.4
F-Score6
WACC9.6%
ROIC/WACC2.49
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.59%
EBIT Next 3Y32.03%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


What is the profitability of RIGL stock?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


Can you provide the financial health for RIGL stock?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.


What is the earnings growth outlook for RIGEL PHARMACEUTICALS INC?

The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to decline by -36.48% in the next year.